c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment
Maria Rosaria Raspollini1, Gianni Amunni, Alessandro Villanucci
1Department of Human Pathology and Oncology, University of Florence, Florence, Italy. mariarosaria.raspolini@unifi.it
Purpose:
Uterine leiomyosarcomas are rare tumors characterized by their resistance to chemotherapy and radiation treatment. Surgery is the primary method of treatment, but for patients with unresectable disease, alternate therapeutic options are clearly warranted. According to initial observations of c-KIT expression, correlation with a bad prognosis, and the successful therapeutic possibility of STI571 in gastrointestinal stromal tumors, the data have encouraged us to study c-KIT expression in these tumors.
Experimental Design:
We analyzed the expression of c-KIT and genetic assessment of exon 11 of c-kit gene in 32 uterine leiomyosarcomas.
Results:
In 17 cases (53.1%), we observed a c-KIT expression in tumor cells. Of the 17 patients with distinct c-KIT-positive immunoreactivity, eight had I or II stage disease and nine had III or IV stage disease. Molecular genetic analysis of exon 11, analyzed by direct DNA sequencing, was performed for all of the c-KIT-positive uterine leiomyosarcomas. No mutations were found.
Conclusion:
The conventional chemotherapy in leiomyosarcomas appears to be ineffective for patients with metastatic or unresectable disease, and the management of these patients poses a special problem. In these women, new therapeutic strategies are warranted. The treatment with STI571 in leiomyosarcoma patients might be hypothesized, because uterine leiomyosarcomas also express c-KIT.
Insights
Uterine leiomyosarcomas express c-KIT, a protein targeted by STI571. This suggests a potential new treatment strategy for patients with unresectable or metastatic disease, as conventional therapies are often ineffective.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Uterine leiomyosarcomas are rare and often resistant to standard treatments like chemotherapy and radiation.
- Surgery is the primary treatment, but options for unresectable cases are limited.
- Previous studies showed c-KIT expression in other tumors and successful treatment with STI571.
Purpose of the Study:
- To investigate the expression of c-KIT in uterine leiomyosarcomas.
- To assess the potential of targeting c-KIT for therapeutic purposes in these tumors.
- To correlate c-KIT expression with disease stage.
Main Methods:
- Analysis of c-KIT expression in 32 uterine leiomyosarcoma samples using immunohistochemistry.
- Genetic assessment of exon 11 of the c-kit gene via direct DNA sequencing in c-KIT positive cases.
Main Results:
- c-KIT expression was observed in 53.1% (17 out of 32) of uterine leiomyosarcomas.
- No mutations in exon 11 of the c-kit gene were detected in the c-KIT positive samples.
- c-KIT expression was present in both early (Stage I/II) and advanced (Stage III/IV) disease.
Conclusions:
- Uterine leiomyosarcomas express c-KIT, indicating a potential therapeutic target.
- The drug STI571, which targets c-KIT, may be a viable treatment option for patients with unresectable or metastatic uterine leiomyosarcoma.
- New therapeutic strategies are needed for patients with advanced or unresectable uterine leiomyosarcoma.
